

IELSG Newsletter 38 - December 2011

Dear friends,
another fruitful year has passed. We summarize here the highlights.

1. NEWS FROM THE ASH MEETING

This year again the IELSG was present at the ASH meeting, which has been held in San Diego in the beginning of December. Two IELSG oral presentations have been well received by the audience.

S. Govi et al. on the final results of the IELSG 27 study (session on Novel Biologic Approaches to Indolent Lymphoma)

S. Sammassimo et al. suggesting a possible pathogenetic role of *Achromobacter* *Xylooxidans* in BALT Lymphomas, IELSG 28 study (session on Rare Lymphoma Subtypes)

The abstracts are posted in the IELSG website (www.ielsg.org).

The IELSG Operation Office and Board of Directors thank all the colleagues who contributed to these successful studies. These are outstanding achievements for our group. The participation of biologists, pathologists and clinicians from different countries in the IELSG studies has allowed a valuable progress in our understanding of the infectious pathogenesis of MALT lymphomas.

We have now to face the challenge of improving upon and maintaining our high-quality scientific output.

2. STUDIES STILL OPEN FOR ENROLLMENT

IELSG 30 - A phase II study of R-CHOP with intensive CNS prophylaxis and scrotal irradiation in patients with primary testicular diffuse large B-cell lymphoma

IELSG 32 - Randomized phase II trial on primary chemotherapy with high-dose methotrexate and high-dose cytarabine with or without thiotepa, and with or without rituximab, followed by brain irradiation vs. high-dose chemotherapy supported by autologous stem cells transplantation for immunocompetent patients with newly diagnosed primary CNS lymphoma

IELSG 33 - A Prospective observational study of newly diagnosed diffuse large B cell primary breast lymphomas treated with R-CHOP with or without radiotherapy

IELSG 17 - Multi-institutional retrospective analysis of intravascular lymphomatosis

IELSG 28 - A retrospective international clinico-pathological study of primary extranodal marginal zone lymphoma of the lung (BALT-lymphoma)

IELSG 31 - A retrospective international study of primary extranodal follicular lymphoma

IELSG 35 - A retrospective international study of primary extranodal lymphoma of female genital tract

3. OPENING SOON

The IELSG 37 trial to compare radiation therapy vs. observation in patients with **primary mediastinal large cell lymphoma achieving a complete remission (PET negative)** will be open soon.

This study will need dedicational commitment from all IELSG centers in the world, but might hopefully provide important clinical information for the treatment of this challenging disease.

4. IELSG PUBLICATIONS 2011

Nicolosi Guidicelli S, Lopez-Guillermo A, Falcone U, Conconi A, Christinat A, Rodriguez-Abreu D, Grisanti S, Lobetti-Bodoni C, Piffaretti JC, Johnson PW, Mombelli G, Cerny A, Montserrat E, Cavalli F and Zucca E. **Hepatitis C virus and GBV-C virus prevalence among patients with B-cell lymphoma in different European regions: a case-control study of the International Extranodal Lymphoma Study Group**

Hematological Oncology 2011 September (Epub ahead of print)

Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, Bottelli C, Conconi A, Gomez H, Lopez-Guillermo A, Martinelli G, Merli F, Novero D, Orsucci L, Pavone V, Ricardi U, Storti S, Gospodarowicz MK, Cavalli F, Sarris AH, Zucca E. **First-line treatment for primary testicular diffuse large B-cell lymphoma with Rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial** Journal of Clinical Oncology 2011 July; 29(20): 2766-2772

Mian M, Gaidano G, Conconi A, Tsang R, Gospodarowicz MK, Rambaldi A, Rossi A, Oldani E, Federico M, Luminari S, Bellei M, Pogliani EM, Rossini F, Cabrera ME, Martelli M, Lopez-Guillermo A, Busetto M, Cavalli F, Zucca E and Cortelazzo S. **High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large b-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study** Leukemia and Lymphoma 2011 May; 52(5): 823-832

Mian M, Marcheselli L, Luminari S, Federico M, Cantonetti M, Sarris AH, Rossi A, Rambaldi A, Frontani M, Devizzi L, Gianni AM, Busetto M, Berti E, Martinelli G, Tsang RW, Ferreri AJ, Pinotti G, Pogliani E, Zucca E, Cortelazzo S. **CLIP1: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11)** Annals of Hematology 2011 Apr 90(4): 401-408

Conconi A, Martinelli G, Lopez-Guillermo A, Zinzani PL, Ferreri AJ, Rigacci L, Devizzi L, Vitolo U, Luminari S, Cavalli F, Zucca E. **Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)** Annals of Oncology March 2011; 22(3): 689-95

Moreover, papers concerning IELSG trials have been submitted for publication: IELSG 19 to the JCO, IELSG 23 to The Oncologist, IELSG 29 to the BJH.

5. 2012 IELSG ANNUAL MEETING

As previously announced the **next IELSG annual Meeting will be held in Lugano, April 20-21 2012** in connection with the **Educational Cancer Convention Lugano (ECCLU)**, which will be devoted to haemato-oncology (see www.eso.net/events-2.html)

VENUE

Hotel de la Paix

CH-6900 Lugano, via Cattori 18

phone +41 (0)91 960 60 60

fax +41 (0)91 960 60 66

e-mail booking@delapaix.ch

website www.delapaix.ch

REGISTRATION

Deadline: March 20, 2012

Registration for the meeting is free of charge and should be done online at www.ielsg.org/meetingsfr.html

ACCOMMODATION

Get in touch directly with the hotel to book your own room specifying the IELSG meeting as the reason of your stay, so that you will be charged at a special discount rate: CHF 195 per night, single room, CHF 270 double room. This discounted offer expires on **March 20, 2012**. It is therefore very important that you book your room **as soon as possible**. After March 20 the room booking will only be possible according to hotel availability and at a full price.

Looking forward to seeing you at our annual meeting we wish you a merry Christmas and a very happy 2012

F Cavalli, E Zucca, A Stathis, A Conconi, C Morinini, E Porro, R Gianascio



STUDIES COORDINATION OPERATION OFFICE

IELSG

International Extranodal Lymphoma Study Group

Oncology Institute of Southern Switzerland - San Giovanni Hospital
CH-6500 Bellinzona - SWITZERLAND

phone ++41 91 811 9040-9060-9041 - fax ++41 91 811 9182

e-mail ielsg@ticino.com - www.ielsg.org